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Behavioral hypersensitivity is common following spinal cord injury (SCI), producing significant discomfort and often developing
into chronic pain syndromes. While the mechanisms underlying the development of behavioral hypersensitivity after SCI are poorly
understood, previous studies of SCI contusion have shown an increase in amino acids, namely, aspartate and glutamate, along with
a decrease in GABA and glycine, particularly below the injury. The current study sought to identify alterations in key enzymes and
receptors involved in mediating central inhibition via GABA and glycine after a clinically-relevant contusion SCI model. Following
thoracic (T8) 25.0 mm NYU contusion SCI in rodents, significant and persistent behavioral hypersensitivity developed as evidenced
by cutaneous allodynia and thermal hyperalgesia. Biochemical analyses confirmed upregulation of glutamate receptor GluR3 with
downregulation of the GABA synthesizing enzyme (GAD65/67 ) and the glycine receptor 𝛼3 (GLRA3), notably below the injury.
Combined, these changes result in the disinhibition of excitatory impulses and contribute to behavioral hyperexcitability. This
study demonstrates a loss of central inhibition and the development of behavioral hypersensitivity in a contusive SCI paradigm.
Future use of this model will permit the evaluation of different antinociceptive strategies and help in the elucidation of new targets
for the treatment of neuropathic pain.

1. Introduction
In addition to having to cope with the debilitating locomotor
and autonomic consequences of spinal cord injury (SCI), the
majority of individuals also develop chronic pain syndromes,
regardless of the severity of the injury or the degree of
motor recovery achieved [1–3]. Neuropathic pain after SCI
is mainly characterized by severe allodynia, which is a
heightened response to a stimulus, either mechanical or
thermal, that would otherwise evoke little or no pain [4, 5].
In experimental SCI models, structural and chemical changes
within the injured spinal cord lead to the development of
behavioral hypersensitivity as characterized by the appearance of mechanical allodynia and thermal hyperalgesia on

dermatomes at, above, and/or below the level of injury [4, 6].
Although these symptoms have been shown to arise from
neuronal hyperexcitability in the dorsal horn, resulting from
enhanced excitatory amino acid (EAA) signaling [7, 8] and/or
loss of central inhibition [9], the underlying mechanisms
responsible for these sensory changes remain poorly understood. Further elucidation of the signaling intermediaries
involved in this altered neurotransmission after SCI is critical
for the identification of putative therapeutic targets for the
treatment of neuropathic pain.
Nociceptive signals are carried by both myelinated A𝛿
and unmyelinated C fibers in the spinal cord. After SCI, there
is an observed increase in levels of glutamate and aspartate, EAAs responsible for mediating excitatory impulses
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via ligand-gated ionotropic receptors, including NMDA and
AMPA [7, 8]. Upregulation of AMPA receptors, which are
responsible for gating the majority of fast synaptic transmission in the central nervous system (CNS), creates a
hyperexcitable state in the spinal cord below the site of
injury [10–13]. Blocking glutamate receptors below the injury,
such as GluR3, a subunit of the AMPA receptor family, has
been shown to decrease the hyperexcitability of dorsal horn
neurons and lessen mechanical allodynia in rats with severe
contusive SCI [14, 15]. Concomitantly with an increased
activation of excitatory neurotransmitter receptors after SCI,
there is a decline in inputs from inhibitory neurotransmitters
such as GABA and glycine [16–18]. GABA is the primary
inhibitory neurotransmitter in the spinal cord and it plays
an antinociceptive role under both normal and pathological
conditions [19]. Reduced GABAnergic tone after a peripheral
nerve or a spinal cord injury disinhibits excitatory impulses
and lowers nociceptive thresholds [20–22]. When GABA
receptors are stimulated in noninjured rats using GABAA and
GABAB receptor agonists, animals show reduced mechanical
allodynia [23–25]. Glutamate decarboxylase (GAD) is a
GABA synthesizing enzyme that is found in two forms,
GAD65 and GAD67 , within the axonal bouton and the cell
body, respectively [26, 27]. There is evidence that dysregulation of these two enzymes occurs in the dorsal horn of the
spinal cord after an injury [22, 28]. Glycinergic signaling is
also reduced under neuroinflammatory conditions, including
SCI, with an inhibition of glycine receptors, such as glycine
receptor 𝛼3 (GLRA3) [16, 29, 30]. Inflammation increases the
expression of the enzyme cyclooxygenase-2 (COX-2) and the
production of prostaglandin E2 (PGE2 ), a GLRA3 antagonist.
PGE2 blocks GLRA3 via a protein kinase A (PKA) pathway,
making these receptors unresponsive to the inhibitory effects
of glycine [31, 32]. Overall a lack of central inhibition from
reduced levels of GAD65/67 and the muted state of GLRA3
and increased excitatory activity, via the upregulation of
GluR3, are the main contributors to a hypersensitive state to
peripheral stimuli after SCI [16].
The current study sought to explore the plasticity of the
sensory system in a clinically-relevant SCI model with the
goal of elucidating new pharmacological targets for the treatment of chronic pain. The MASCIS (25.0 mm weight drop)
thoracic T8 contusion model produces a highly reproducible
manifestation of persistent behavioral hypersensitivity that
has been previously characterized [33–35] and is similar to
the symptoms observed in a high percentage of humans
after SCI [36, 37]. Rather than focus on the dysregulation
of inhibitory (GAD65/67 and GLRA3) and excitatory (GluR3)
neurotransmission within the dorsal horn, near to the injury,
in the present work the temporal (1 and 12 weeks) and
spatial expression profiles of these markers were investigated
along the thoracic and lumbar cord. These biochemical
changes were examined in relation to the development of
allodynic and hyperalgesic responses on the paw and torso
dermatomes. The current study provides new insight into
the dysregulation of neurotransmission following SCI and
the development of neuropathic pain, providing novel targets
that could be used for the design of treatments for chronic
pain clinically.
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2. Materials and Methods
2.1. Animals. Adult female Fischer rats (Harlan Co., 𝑛 = 24;
180–200 g) were housed according to NIH standards and
The Guide for the Care and Use of Animals. The Institutional Animal Care and Use Committee of the University
of Miami approved all animal procedures. Prior to surgery,
rats were anesthetized intraperitoneally (45 mg/kg ketamine
and 5 mg/kg xylazine) and a reflex test was performed to
assess that an adequate level of anesthesia had been attained.
Lacrilube ophthalmic ointment (Allergan Pharmaceuticals,
Irvine, CA) was applied to the eyes to prevent drying. During
surgery, the animals were kept on a homeothermic blanket
system (Harvard Apparatus Ltd., Kent, England) to maintain
the body temperature at 37 ± 0.5∘ C as measured by rectal
probe.
2.2. Contusive Spinal Cord Injury. A moderate contusion
injury was induced by the weight drop device developed at
New York University [33]. Following anesthesia, a vertical
incision was made along the thoracic vertebra and the
superficial muscle and skin retracted. A laminectomy was
performed at the thoracic vertebra T8 to expose the dorsal
surface of the spinal cord underneath (T9) without disrupting
the dura mater. Stabilization clamps were placed around the
vertebrae at T6 and T12 to support the column during impact.
The exposed spinal cord was moderately injured by dropping
a 10.0 g rod from a height of 25.0 mm. The contusion impact
height, velocity and compression were monitored. Animals
(𝑛 = 2) were excluded immediately when height or velocity
errors exceeded 7% or if the compression distance was not
within the range of 1.75–2.25 mm. After injury, the muscles
were sutured in layers and the skin closed with metal wound
clips. The animals were allowed to recover in a warmed cage
with water and food easily accessible. Postoperative care,
including the administration of antibiotics, analgesics, and
fluids, was performed as described elsewhere [38, 39]. Survival times were one week and twelve weeks after injury for
the assessment of acute and chronic protein levels of GluR3,
GAD65/67 , and GLRA3 above (T5/6) and below (T10/11, L2,
and L5) the injury site. Animals were randomly placed into
four groups for further analyses: (i) acute noninjured (𝑛 = 6),
(ii) chronic noninjured (𝑛 = 6), (iii) acute SCI only (𝑛 = 6),
and (iv) chronic SCI only (𝑛 = 6).
2.3. Behavioral Testing
2.3.1. Cutaneous Allodynia Evaluation. The hind limbs and
back of the rats were tested for cutaneous allodynia using
an electronic von Frey anesthesiometer (IITC Life Science
Inc., Woodland Hills, CA). The animals were acclimatized to
human handling by placing them in a clear Plexiglas testing
apparatus (8 × 8 × 18 cm) for 4 hours daily for 14 days prior
to testing. Preoperative testing began 1 week before injury to
establish both individual and group baseline behaviors. After
injury, tests were performed at weekly intervals for twelve
weeks. Before testing, animals were allowed a 30-minute
acclimation period to the apparatus. Once acclimatized, the
device tip was applied perpendicular to the specific places on
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the ventral midplantar glabrous skin of both hind paws and
on the dorsal skin dermatomes (caudal, rostral, and at level
of the injury) and depressed slowly until the animal elicited a
response from pressure. The value, in grams, was recorded for
each of the 3 trials. A single trial of stimuli consisted of three
to four applications of the von Frey tip within a 10-second
period, to ensure a consistent response. The values obtained
for each hind paw were averaged and the standard error of the
mean (SEM) calculated. Responses to the stimulus included
withdrawal, head turning, and postural changes in normal
rats.
2.3.2. Thermal Hyperalgesia Assessment. Paw-withdrawal
response to a noxious thermal stimulus was assessed using
a Hargreaves device [40]. The animals were first placed in a
clear Plexiglas box mounted on an elevated Plexiglass floor.
Animals were then allowed to acclimatize for approximately
30 minutes. A radiant heat source with a constant-intensity
(i.e., 2.5 V) was aimed individually at the ventral midplantar
surface of each one of the animal’s hind paws. The time, in seconds, from initial heat source activation (normally noxious
stimulus) until paw withdrawal, was recorded. A five-minute
rest period was allowed between successive stimulation. Four
latency measurements for each hind paw were recorded at
weekly sessions and the mean and the SEM were calculated
for each hind paw.
2.4. Biochemistry
2.4.1. Western Blot Analysis. Acute and chronic protein
expression levels of the GABA-synthesizing enzymes
GAD65/67 , the glycine receptor GLRA3, and the AMPA
receptor GluR3 were detected by immunoblotting as
described previously [36]. Blocks of spinal cord (3 mm
in length) taken immediately above the injury (T5-6),
immediately below the injury (T10-11), and from the lumbar
cord (L2 and L5), one week and twelve weeks after injury
were evaluated. Equal amounts of spinal cord lysates were
added to 5x SDS-PAGE sample buffer (0.225 M Tris-Cl, pH
6.8, 50% glycerol, 5% SDS, 0.05% bromophenol blue, and
0.25 M dithiothreitol). The mixture was heated for 5 minutes
at 95∘ C then centrifuged for 5 minutes. The samples were
loaded into a polyacrylamide gel (Lonza PAGEr Gold Gels
10–20%) in equal amounts (10 𝜇L per lane). Proteins were
separated using SDS-page gel electrophoresis and transferred
to polyvinylidene fluoride (PVDF) membranes at 100 V for
90 minutes in transfer buffer (25 mM Tris base, 150 mM
glycine, and 20% methanol). The PVDF membranes were
blocked overnight in blocking solution (2% Amersham
ECL blocking agent in TBS-Tween). The following day,
they were incubated with antibodies against GAD65/67
(1 : 50,000), GluR3 (1 : 10,000), and GLRA3 (1 : 10,000) diluted
in blocking solution for 60 minutes and washed four times
in TBS-Tween for 10 minutes. After washing, the membranes
were incubated with HRP-conjugated goat anti-rabbit IgG
(1 : 10,000; Santa Cruz) for 60 minutes and washed again four
times in TBS-Tween for 10 minutes. The membranes were
treated with the Western Lightning Ultra Extreme Sensitivity
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Chemiluminescence reagent (PerkinElmer) for antibody
binding detection. Quantification of bands corresponding
to changes in protein levels was made using scanned
densitometric analysis and the NIH Image Program 1.62f.
2.5. Data and Statistical Analysis. All analyses were conducted upon the completion of behavioral testing or histological preparation by an individual blinded to the animal’s
treatment. For statistical analyses of cutaneous allodynia and
thermal hyperalgesia data, hind paw values were compared
using a one-way ANOVA with a Bonferroni posttest and
skin values were compared using repeated measures ANOVA
with Bonferroni posttest. The density of immunoblot bands
in different spinal cord regions was compared independently
among the groups by one-way ANOVA with a Bonferroni
posttest. Statistical significance was accepted at 𝑃 < 0.05.

3. Results
3.1. Moderate Contusive SCI Produces Persistent Cutaneous
Allodynia and Thermal Hyperalgesia. To measure behavioral
hypersensitivity on the paw and torso dermatomes, cutaneous allodynia with definite responses indicative of pain and
thermal hyperalgesia were evaluated at 1 week before injury,
as a baseline, and weekly after SCI for 12 weeks. For baseline
recordings, the average pressure required to elicit a painful
withdrawal response of both hind paws was 30.7 ± 0.8 g. In
the noninjured group, subsequent recordings over 12 weeks
did not vary significantly from this baseline value (𝑃 >
0.05). In contrast, following SCI, a pronounced reduction in
the pressure required to elicit a painful response with the
von Frey filament was observed, with average withdrawal
pressures of 17.3 ± 1.6 g (𝑃 < 0.001) and 16.3 ± 0.7 g (𝑃 <
0.001) at weeks 2 and 12, respectively (Figure 1).
Upon the torso, cutaneous allodynia was evaluated at
three different levels: above the injury (level +1), at the
injury level (level 0), and below the injury (level −1), at
points along the midline and laterally on both sides of
the back as illustrated in Figure 2. Compared to uninjured
controls, in which no significant changes were observed on
torso dermatomes for the 13 week duration of the study, a
pronounced and persistent reduction in the pressure required
to elicit a painful response was noted after SCI at, above, and
below the level of injury from week 2 to endpoint. At 2 weeks
after SCI, the pressure required to elicit a painful response
had decreased by up to 78.6% (𝑃 < 0.001), 79.1% (𝑃 < 0.001),
and 72.8% (𝑃 < 0.001), respectively, at levels +1, 0, and
−1 compared to baseline values (Figure 2). This pronounced
allodynia persisted through 12 weeks with endpoint pressure
reductions of 85.7% (𝑃 < 0.001), 87.2% (𝑃 < 0.001), and
81.2% (𝑃 < 0.001), respectively, at levels +1, 0, and −1
compared to baseline values.
The evaluation of thermal hyperalgesia on the hind
paws of uninjured animals provided baseline withdrawal
values of 14.7 ± 0.91 s from the heat source. Two weeks
after SCI, animals exhibited a 23.4% increase in withdrawal
times (11.3 ± 1.1 s, 𝑃 < 0.001) compared to baseline
values, indicating a greater sensitivity to the noxious thermal
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Figure 1: Significant increases in cutaneous allodynia on the hind
paws were observed in the injured group when compared to noninjured controls. Compared to preinjury, baseline, and uninjured
control withdrawal thresholds, the withdrawal responses for the
injured group after SCI were significantly lower from 2 to 12 wks after
SCI. Similar values were observed up to 12 wks after injury.

stimulus (Figure 3). The degree of hyperalgesia on the hind
paws persisted through endpoint, with a 30.9% increase in
withdrawal times at 12 weeks after SCI (11.6 ± 0.8 s, 𝑃 <
0.001), compared to uninjured recordings.
3.2. Increases in Markers of Glutamatergic Neurotransmission
and Decreases in Glycinergic and GABAnergic Signaling Are
Observed after Contusive SCI. GluR3, GAD65/67 , and GLRA3
levels were evaluated by immunoblotting in spinal cord
samples taken from above (T5/6) and below (T10/11, L2, and
L5) the injury site. Protein production was assessed at 1 week
(acute) or 12 weeks (chronic) after SCI for comparison to
analogous regions taken from uninjured controls.
Expression of the AMPA receptor GluR3, for the excitatory neurotransmitter glutamate, showed increases both
acutely and chronically after SCI at all levels of the spinal cord
(Figure 4). Above the level of SCI (T5/6), GluR3 expression
increased 12.9% (𝑃 < 0.001) and 58.6% (𝑃 < 0.001) at 1 and
12 weeks after injury, respectively. Similar increases in GluR3
expression were observed at T10/11 level, 15.8% (𝑃 < 0.001)
and 61.7% (𝑃 < 0.001), respectively, at 1 and 12 weeks after
SCI. Below the level of injury (at L2 and L5), GluR3 expression
increased significantly and sooner after SCI and at 1 week (L2,
44.2% increase, 𝑃 < 0.001; L5, 56.1% increase, 𝑃 < 0.001) and
12 weeks (L2, 67.2% increase, 𝑃 < 0.001; L5, 54.5% increase,
𝑃 < 0.001) after injury compared to uninjured controls.
GABAnergic signaling was assessed using immunoblot
detection of the GABA-synthesizing enzymes GAD65/67 (Figure 5). Although significant reductions in GAD65/67 were
observed at all levels of the spinal cord at 12 weeks after SCI,

at 1 week after injury no changes were observed above the
level of SCI, only below the injury site. Above the level of
SCI, there was a 58.9% reduction in GAD65/67 (𝑃 < 0.001) at
12 weeks, but not 1 week after injury compared to uninjured
controls. Decreased GAD65/67 expression was also observed
at the T10/11 level, 20.5% (𝑃 < 0.001) and 65.6% (𝑃 < 0.001),
respectively, at 1 and 12 weeks after SCI. Below the level of
injury (at L2 and L5), GAD65/67 expression decreased more
significantly and sooner after SCI than levels detected above
the injury site and at 1 week (L2, 38.3% decrease, 𝑃 < 0.001;
L5, 46.3% decrease, 𝑃 < 0.001) and 12 weeks (L2, 48.3%
decrease, 𝑃 < 0.001; L5, 51.1% decrease, 𝑃 < 0.001) after
injury compared to uninjured controls.
The glycine receptor, GLRA3, was used as a marker
for glycinergic signaling. Like GAD65/67 , GLRA3 showed
pronounced and persistent decreases in expression along the
spinal cord after SCI (Figure 6). Above the level of SCI,
there was a 21.1% reduction in GLRA3 (𝑃 < 0.001) at 12
weeks after injury but no change at 1 week compared to
uninjured controls. Decreased GLRA3 expression was also
observed at T10/11 level, 31.1% (𝑃 < 0.001) and 34.2% (𝑃 <
0.001), respectively, at 1 and 12 weeks after SCI. Below the
level of injury (at L2 and L5), GLRA3 expression decreased
significantly and sooner after SCI than levels detected above
the injury site and at 1 week (L2, 30.5% decrease, 𝑃 < 0.001;
L5, 29.6% decrease, 𝑃 < 0.001) and 12 weeks (L2, 36.4%
decrease, 𝑃 < 0.001; L5, 37.6% decrease, 𝑃 < 0.001) after
injury compared to uninjured controls.

4. Discussion
Neuropathic pain is a major secondary complication after
SCI. Approximately 65% of SCI individuals report hypersensitivity at or below level of injury, and 30% of those
individuals classify the pain as excruciating [2, 3, 41, 42]. The
present study used a clinically-relevant, moderate contusion
SCI model in the adult rat to investigate the behavioral
sequelae and main molecular mechanisms that underlie the
manifestation of central pain after SCI. Several groups have
shown previously that SCI-related neuropathic pain is due,
in part, to an increase in excitability in the CNS parallel to
a decrease in inhibitory inputs from the spinal dorsal horn
[6, 18, 42]. The summation of these two events leads to a
hyperexcitable state in the CNS and the emergence of pain
syndromes [37]. Temporal and spatial behavioral and molecular data from the present study supports the hypothesis
that reductions in inhibitory GABAnergic and glycinergic
signaling, via GAD65/67 and GLRA3, and increased excitatory
glutamatergic signaling, via GluR3, are involved in neuronal
hyperexcitability and the ensuing manifestation of neuropathic pain following SCI.
GABA and glycine are the two major molecules involved
in fast inhibitory transmission in the CNS [43, 44].
GABAnergic and glycinergic fibers descend from supraspinal
sites and innervate the dorsal horn directly. Their role in sensory processing occurs through post and presynaptic interaction of GABAnergic and glycinergic dorsal horn neurons and
interneurons with other nearby neurons, as well as with spinal
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Figure 2: Continued.
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Figure 2: Manifestation of allodynia on the cutaneous surface of the back over time after contusive SCI. Before injury, the force required to
elicit a response was equal at all points. Within 9 days after the contusion, the force was reduced 4-5-fold in all areas, with the epicenter (level
0) showing the greatest hypersensitivity. This same pattern persisted up to 90 days after SCI. Overall, a 10-fold increase in tactile allodynia
was observed on the back of the animals with SCI. The data are expressed as means.
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Figure 3: Thermal hyperalgesia developed in both hind paws, as
evidenced by a decrease in paw withdrawal thresholds. At 2 weeks
after injury, the withdrawal responses for both hind paws were
significantly lower than the baseline withdrawal threshold, which
was measured at 1 week before SCI. Similar values were observed up
to 12 wks. Compared to preinjury, baseline, and uninjured control
withdrawal thresholds, after SCI the withdrawal responses for the
injured group was significantly lower from 2 to 12 wks after SCI.
Similar values were observed up to 12 wks after injury.

sensory axon terminals [18]. GABA is synthesized in the
neurons from glutamic acid by the enzyme GAD (with two
isoforms GAD65/67 ). GABAnergic neuronal cell bodies can be
found in the grey matter, particularly in the superficial laminae I–III of the dorsal horn, where they receive input from
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Figure 4: Protein expression of the AMPA receptor GluR3 as
detected by immunoblotting. At both acute (1 week) and chronic
(12 wks) time points, the protein expression of GluR3 increased at all
levels of the spinal cord, but most notably at the lumbar level. This
increase was even more notable on week 12, at T5/6, T10/11, and L2,
however; the expression of GluR3 at L5 did not change significantly
from week 1.

myelinated A𝛿 and unmyelinated C-fibers and thus help regulate nociceptive transmission [45–48]. Trauma to the spinal
cord triggers several cascades of neurochemical events at the
local level that cause changes in pain perception throughout
the nervous system. The initial signal may possibly come
from damaged fibers in the dorsal horn, which then activate
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Figure 5: Protein expression of the GABA synthesizing enzyme
GAD65/67 as detected by immunoblotting. There was a decrease in
GAD65/67 expression at all levels, both in the acute and chronic
paradigms. However, the downregulation of GAD65/67 was most
noticeable at 12 wks. In the earlier time point, especially above the
injury site (T5/6), the expression of GAD65/67 decreased slightly but
continued a steady decline at all of the other levels.

Figure 6: Protein expression of the glycine receptor GLRA3 as
detected by immunoblotting. At 1 week as well as at 12 wks, the
protein expression of GLRA3 had downregulated at all levels of
the spinal cord, but most notably below the injury site. Acutely,
GLRA3 values showed only a small decrease at T5/6. However, this
downregulation became more apparent at the other three levels. The
same pattern was seen in the chronic paradigm.

microglia to release the neurotrophic factor BDNF. BDNF in
turn binds to trkB receptors, causing the downregulation of
the potassium chloride exporter KCC2 and the depolarization of dorsal horn neurons [18]. The intracellular chloride
ion gradient is controlled synergistically by neurons and glial
cells, which modulate chloride transporters as well as GABA
and glutamate concentrations in order to maintain a proper
balance of chloride ions [21]. However, once the expression
of KCC2 is reduced, chlorine homeostasis is altered leading
to a decrease in GABAnergic inhibitory transmission, which
results in sensory hypersensitivity [6, 47]. Injury also causes
the loss of GABAnergic neurons and interneurons in the
spinal superficial dorsal horn through caspase-3 activation, in
addition to a downregulation in the expression of GAD65/67 ,
especially within laminae I–III of the dorsal horn [47]. However, the exact mechanisms underlying the downregulation of
GAD65/67 have not yet been fully elucidated. One hypothesis
put forth by Gwak and Hulsebosch is that the upregulation
of glutamate following SCI, combined with an increase of
other pain promoting molecules released by glial cells, such
as ATP, IL-1, IL-6, TNF, NO, and ROS, triggers intracellular
downstream cascades that affect GAD gene expression [21].
Glycine is a ubiquitous amino acid and it is the second
most important fast inhibitory neurotransmitter in the CNS
[43, 49]. Glycinergic neurons are localized throughout the
spinal grey matter, overlapping with GABAnergic neurons,
although they are more localized to deeper layers of the dorsal
horn (laminae III-IV) [46]. Neurons in deeper dorsal horn
laminae can receive inputs from GABAnergic and glycinergic

synapses at the same time, since both neurotransmitters
can be released concomitantly [50–53]. As for the glycine
receptors, most are heteromeric and contain four 𝛼 subunits
(GLRA1-4) and one 𝛽 subunit, but in the adult nervous
system subunit 𝛼1 is the most abundant. Our experiment
focuses on the glycine receptors containing subunit 𝛼3
(GLRA3), since it has been established that they are involved
in inflammatory responses. GLRA3 is not a widely expressed
subunit, but it can be found in the more superficial layers of
the dorsal horn where nociceptive A𝛿- and C-fiber afferents
terminate [54].
Chronic inflammatory pain after SCI is marked not
only by a decrease in GABAnergic tone in the dorsal horn,
as discussed above, but also by a decline in glycinergic
inhibition. Fast inhibition in the spinal cord by both GABA
and glycine occurs mainly in presynaptic terminals [55].
However, glycine is the main component responsible for
the postsynaptic transmission occurring in superficial levels
of the adult dorsal horn [32, 54]. The inhibition of this
type of glycinergic transmission is thought to be regulated
by the inflammatory mediator prostaglandin E2 (PGE2 ),
which is mainly localized in the superficial layers of the
dorsal horn where most terminals for nociceptive fibers are
found. Peripheral inflammation causes an upregulation in the
production of PGE2 by COX-2 and prostaglandin E synthase
in the spinal cord [56]. In turn, postsynaptic PGE receptors of
the EP2 subtype are activated and trigger a G-protein coupled
cascade that increases intracellular levels of cyclic adenosine
monophosphate (cyclic AMP). Protein kinase A (PKA),
which is activated by cyclic AMP, goes on to phosphorylate
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and inhibit glycine receptors containing the 𝛼3 subunit [30,
32, 54]. Studies using rodent models have shown that the inhibition of glycinergic transmission in the superficial layers of
the dorsal horn contributes to both mechanical allodynia and
thermal hyperalgesia [57–59]. Thus, increasing the inhibitory
tone in the CNS through the modulation of the glycine
receptor subtype GLRA3 is a potential pharmacological target
for the treatment of neuropathic pain after SCI.
Glutamate is the major excitatory neurotransmitter in
the CNS and, as such, it is a crucial component for mediating excitatory synaptic transmission [60]. There are several
receptors for glutamate, but it has been well established
that the AMPA receptor subtype plays a powerful role in
fast excitatory currents and, consequently, in the stimulation of pain behavior [61–63]. Most AMPA receptors are
heterotetrameric structures with four subunits (GluR1-4).
In 2008, Polgár and colleagues studied the localization of
AMPA receptors in the adult rat spinal cord and concluded
that most glutamatergic synapses in laminae I–III of the
dorsal horn contain AMPA receptors [62]. GluR1 is the most
abundant subtype in laminae I and II where it overlaps
with GluR2 and/or GluR3, while GluR4 is confined to some
lamina I projection cells. In the present investigation we
focused on the expression of the less studied GluR3 after
SCI. The combination of diminished inhibitory inputs from
dorsal horn neurons along with a rise in the excitatory tone
driven by the neurotransmitter glutamate leads to a chronic
hypersensitive state. Gwak and Hulsebosch have shown that
after injury there is a prolonged activation of dorsal horn
neurons due to an increase in glutamate-driven excitation
[21]. In adult rats, the great majority of glutamatergic synapses
in laminae I–III have glutamate receptors of the AMPA type,
which mediate fast excitatory transmission in the dorsal horn
[62, 64]. Polgár and colleagues studied the localization of the
four AMPA receptor subtypes and found that between 57
and 65% of the puncta in laminae I–II and 80% in lamina
III were positive for GluR3 [62]. Their findings along with
data from Tong and Macdermott [12] showed that neurons
expressing AMPA receptors receive primary afferent inputs
associated with pain perception, making them crucial players
in the synaptic transmission between peripheral nociceptive
neurons and spinal cord neurons. Similar to the upregulation
in the production of PGE2 following peripheral inflammation
described previously, noxious peripheral nervous system
(PNS) stimulation also triggers the release of glutamate from
central terminals of primary afferents into the spinal cord
[65]. In turn, glutamate activates AMPA receptors in the
dorsal horn via several protein kinase cascades that phosphorylate these receptors, causing an enhanced response to
painful stimuli [13, 66]. In a rat model of diabetic neuropathy
described by Tomiyama et al. [65], there was an increase in
the levels of mRNAs coding for GluR1, GluR2, and GluR3 in
all layers of the dorsal horn of experimental animals. A great
number of studies have established the role of AMPA receptors in the development of chronic pain, which reinforces
their potential as targets for novel analgesic compounds.
As we have discussed, several molecular mechanisms in
the spinal cord are involved in the sensitization of nociceptive
inputs. Our study focused on the relative temporal and
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spatial changes that occur in the expression of two major
inhibitory transmitters, GABA and glycine, and of the main
excitatory transmitter in the nervous system, glutamate, after
a mechanical trauma to the adult rat spinal cord. Our results
support previous findings that the loss of inhibitory tone from
dorsal horn neurons coupled with an increase in motoneuron
excitability is one of the main molecular pathways implicated
in chronic neuropathic pain following SCI [21, 42, 67] and
that targeting both these systems may offer more effective
therapeutics for ameliorating neuropathic pain after SCI [61].
It is important to reiterate that our immunoblotting results
indicated that GluR3 levels were upregulated while GLRA3
expression was downregulated more notably below the level
of lesion at the acute time point. This observation is also
in accordance to several human studies that have shown
that most SCI-related pain syndromes are reported below
the injury level. This particular type of chronic pain that
is associated with SCI is termed “below-level central pain”
[9, 41, 68, 69]. All three neurotransmitters explored in the current study are major components of the nervous system and,
as such, have been extensively characterized in the literature.
In turn, the focus on their receptors and their potential role
as therapeutic drug agents for the treatment of neuropathic
pain has increased significantly in the pharmacology field. It
is our goal to expand the understanding of these underlying
mechanisms, especially in the context of a clinically-relevant
SCI model, so that new targets can be identified as early
treatment options for the management of neuropathic pain.

5. Conclusions
The current study demonstrates that adult rats with a thoracic
25.0 mm NYU contusion exhibit behavioral hypersensitivity
relevant to human SCI, determined by cutaneous allodynia
and thermal hyperalgesia development, combined with a
loss of central inhibition and enhanced excitability due to
molecular changes in GluR3, GAD65/67 and GLRA3. Future
use of this model will permit us to evaluate how different antinociceptive or regeneration strategies might alter sensory
responses and help in the elucidation of new targets for the
treatment of neuropathic pain.
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